

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number
WO 01/68067 A2

(51) International Patent Classification⁷: **A61K 31/00**

(21) International Application Number: PCT/FI01/00266

(22) International Filing Date: 16 March 2001 (16.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00302207.6 17 March 2000 (17.03.2000) EP

(71) Applicant (*for all designated States except US*): **ORION CORPORATION** [FI/FI]; Orionintie 1, FIN-02200 Espoo (FI).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **KANERVA, Harri** [FI/FI]; Kalkkivuorenkatu 14, FIN-08100 Lohja (FI). **MÄKI-IKOLA, Outi** [FI/FI]; Karhunkatu 32, FIN-20750 Turku (FI).

(74) Agent: **ORION CORPORATION**; Orion Pharma, Industrial Property Rights, P.O. Box 65, FIN-02101 Espoo (FI).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TREATMENT OF DISORDERS RELATING TO THE SEROTONERGIC SYSTEM

(57) Abstract: The present invention relates to deramciclane, (1R,2S,4R)-(-)-2-[N,N-(dimethylaminoethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane, and its use in the treatment of disorders relating to serotonergic system in humans, specifically depression and anxiety.



WO 01/68067 A2

TREATMENT OF DISORDERS RELATING TO THE SEROTONERGIC SYSTEM

5 FIELD OF THE INVENTION

The present invention is directed to deramciclanc, (1R,2S,4R)-(-)-2-[N,N-(dimethylaminoethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane, and its use in the treatment of disorders relating to the serotonergic system. Specifically, the
10 present invention is directed to the use of deramciclanc in the treatment of depression.

Further, the present invention is directed to the use of deramciclanc in the treatment of anxiety, specifically chronic anxiety including GAD, in an oral daily
15 dosage of about 30 mg in humans. The daily dosage may be given as a once-a-day formulation or it may be divided. For example, a once-a-day formulation may be used, and may lead to greater patient compliance than a multiple-dose daily formulation.

20 BACKGROUND

The preparation of deramciclanc as a free base and as a fumarate salt has been described in Hungarian Patent No. 212,547. Other pharmaceutically acceptable acid addition salts of deramciclanc may be formed with inorganic (e.g., hydrochloric acid,
25 sulfuric acid) or organic acids (e.g., acetic acid, tartaric acid). The fumarate salt is an example of such a pharmaceutically acceptable acid addition salt.

Deramciclanc has shown anxiolytic-like effects in some conventional animal models with various routes of administration, and in receptor binding studies *in vitro*
30 deramciclanc has shown to bind with high affinity to serotonin 5HT_{2A}- and 5-HT_{2C}-receptor subtypes, being a potent antagonist of these receptors (Gacsalyi, I. et al., Drug Dv Res (1997) 40:333-348). In punished drinking test in rats (Vogel, J.R. et al.,

Psychopharmacologia (1971) 21:1-7) deramciclane was active, after single oral administration at doses of 1 mg/kg and 10 mg/kg. In social interaction test in rats (File, S.E. J. Neurosci Methods (1980) 2:219-238) deramciclane enhanced the social interaction time in some extend, the minimum effective dose after single
5 intraperitoneal administration was 0.7 mg/kg. In two compartment test in mice (Crawley, J. and F.K. Goodwin, Pharmacol Biochem Behav. (1980)13, 167-170. & Crawley, J.N., Pharmacol. Biochem. and Behav. (1981) 15, 695-699) deramciclane was active after single subcutaneous administration at dose of 3 mg/kg. In marble-burying test in mice (Broekkamp, C.L. et al., Eur J. Pharmacol. (1986) 126:223-229)
10 the effective doses were 10 mg/kg and 30 mg/kg orally. Nevertheless, deramciclane was totally ineffective in elevated plus maze test in rats (Handley, S.L. and S. Mithani, 1984, Effects of Alpha-Adrenoceptor Agonists and Antagonists in a Maze-Exploration Model of "Fear"-Motivated Behaviour, Naunyn-Schmiedeberg's Archives of Pharmacology. 327, 1-5) after single intraperitoneal doses at range of 0.1
15 mg/kg – 5 mg/kg. However, deramciclane was able to attenuate the caerulein-induced decrease in exploratory behavior at an intraperitoneal dose of 0.5 mg/kg in the elevated plus maze test.

Also the possible antidepressant activity of deramciclane has been evaluated in
20 various conventional animal models (Gacsalyi, I. et al., Drug Dv Res (1997) 40:333-348). In learned helplessness test in rat (Giral et al. Reversal of helpless behaviour in rats by putative 5-HT1A agonists. Biol. psychiatry 23: 237- 242), deramciclane dose dependently attenuated helpless behaviour induced by inescapable electric foot shocks, when given intraperitoneally 1 or 10 mg/kg, repeatedly 8 times, twice a day,
25 before the test. The effect of deramciclane was found to be negligible, even at relatively high oral doses, 48-160 mg/kg, when evaluated for tetrabenazine-induced ptosis in mice according to the method of Howard et al. (Howard, J.L. et al., (1981) Empirical behavioral models of depression with emphasis on tetrabenazine antagonism. In Enna S.J., Malick J.B., Richelson E. (eds.): Antidepressants:
30 Neurochemical, Behavioral, and Clinical Perspectives. New York: Raven Press, p 107). In the forced swimming test in rats (Porsolt R.D. et al., Eur. J. Pharmacol. (1978) 47:379-391) deramciclane was clearly ineffective at oral doses of 25 and 100 mg/kg.

Thus, deramciclanc has been effective in some animal models of anxiety after oral doses at range from 1 mg/kg to 30 mg/kg in mice and rats. Further, deramciclanc has showed negligible effects in animal models of depression even after high peroral doses in mice and rats, which is in line with the results reporting that 5-HT_{2C} -
5 receptor agonists are effective in animal models of depression (Moreau J-L. et al. European Neuropsychopharmacology 6:169-175, 1996).

In a whole body autoradiography distribution study with tritium labelled deramciclanc in rats (Hazai, I, et al. J. Pharm. Pharmacol. 51: 165-174, 1999) at a
10 dose of 3 mg/kg, it was found that after intravenous administration there was high radioactivity (reflecting amount of deramciclanc) in several organs including blood and the brain, but after oral administration the amount was substantially lower, especially in the brain.

15 A comparative pharmacokinetic study of orally administered deramciclanc in rats, dogs, rabbits and humans (Klebovich et al Pharm. Pharmacol. Commun., 4: 129-136, 1998), it was shown that the plasma concentration curves obtained after the administration of a single 3 mg/kg oral dose of deramciclanc to rats (dogs, rabbits) and human show considerable species specific differences. In the peak
20 plasma concentration (C_{max}) values there were significant differences: C_{max} was 5.4 ng/ml in rat and 217.5 ng/ml in human after the same 3 mg/kg oral dose. Thus a 40-times lower oral dose of deramciclanc could be used in man to result in the same maximal plasma concentration as in rat. Furthermore, total amount of deramciclanc absorbed into blood, calculated as Area Under Curve values (AUC 0 - ∞) from
25 plasma concentrations as a function of time, showed more considerable species difference. The mean AUC 0 - ∞ values after single oral administration of deramciclanc were 11.9 ng h/ml and 3737.8 ng h /ml in rat and human, respectively. Thus over 300 times lower oral doses should result in equal exposure in humans than in rats. Basing only the C_{max} difference between rat and man, it can be predicted
30 that considerably lower doses should be centrally active in humans than in rat. The minimum oral effective anti-anxiety dose in rats was 1 mg/kg (1-30 mg/kg the full range; see above), i.e. in a 70 kg-man this would mean 70 mg dose. To reach the same pharmacologically active plasma concentration in human as was shown to be

efficacious in rat, one should divide the rat dose by 40. This would result in $70 \text{ mg}/40 = 1.75 \text{ mg}$ (i.e. 0.025 mg/kg) as an effective dose in man.

5 The binding of deramciclane to serotonin 5-HT_{2A} -receptors in frontal cortex of healthy male volunteers after a single oral dose of 20, 50 and 150 mg of deramciclane is discussed in Kanerva, H., et al., Psychopharmacology (1999) 145:76-81. The determination of the brain 5HT_{2A} -receptor occupancy of deramciclane in humans has shown that 90% and 50% receptor occupancies were reached at deramciclane plasma concentration of about 70 ng/ml and 21 ng/ml, 10 respectively. The pharmacokinetics of single dose of deramciclane and during oral dosing of 10 mg, 30mg and 60mg twice a day for seven days are discussed in Kanerva, H., Pharmacokinetic studies on deramciclane. Kuopio University Publications A. Pharmaceutical Sciences 39.1999. After a single oral administration of 20 mg and 30 mg doses of deramciclane, the C_{max} -values were $24 \pm 9.4 \text{ ng/ml}$ and 15 $27 \pm 6.1 \text{ ng/ml}$, respectively. During repeated administration of deramciclane for one week the C_{min} and C_{max} for 60 mg and 20 mg daily doses were shown to range between 48-91 ng/ml and 16-33 ng/ml, respectively.

20 As the above experimental animal and human data does not disclose repeated administration of deramciclane rendering steady state plasma concentrations in a treated patient, it was impossible to foresee the exact oral doses of deramciclane effective in treating anxiety in humans. Furthermore, it was totally unexpected that deramciclane was effective in treating depressive symptoms.

25 Anxiety is a normal emotional feeling related to different situations of threat or fear. External threat is experienced as a fear whereas obscure and unidentified feeling of threat may be experienced as anxiety. When anxiety persists it can develop into a pathological disorder. Anxiety disorders are divided more specifically in diagnostic disorders e.g., panic disorder, phobias, and generalised anxiety disorder (GAD). 30 GAD is a chronic illness associated with excessive anxiety and worry lasting for at least six months. In addition, the anxiety and worry are associated with restlessness, fatigue, difficulties in concentrating or mind going blank, irritability, muscle tension, and sleeping disturbances. The symptoms may be triggered by different events of

life, and the control of anxiety is very difficult to the patient.

Anxiety is currently treated with benzodiazepines, SSRI's and buspirone, which are not optimal treatments regarding the adverse drug reaction and efficacy profiles. Moreover, relapse of the disease, different kinds of withdrawal effects, development of tolerance as well as relapse and recurrence often happen, when traditional anxiolytics are used. For example, to avoid withdrawal effects, the doctors usually gradually taper the dosage of the medicine (i.e. gradually diminish its daily dosage) before the treatment may be stopped. Patients tend to develop tolerance to those traditional compounds as well. Development of tolerance occurs when, for example, a patient requires greater quantities of a compound over time to achieve the same therapeutic effect.

In the treatment of psychiatric disorders with a chronic course, such as anxiety, it is important to prevent the relapse and recurrence of the disease. After the acute treatment phase, the improved condition can be maintained, and relapses can thus be prevented by continuing the treatment in those who have responded to the treatment or who have reached remission during it. After said continuation treatment phase, when recovery has been reached, the disease can be prevented by continuing the treatment further by the so called maintenance treatment, during which the daily dosage may be decreased, for example to a half from the original.

There has thus been a long felt need to obtain an anxiolytic medicament, which is void of withdrawal and discontinuation effects and does not cause development of tolerance in the patients. Furthermore, sufficient efficacy in relapse and recurrence prevention are important qualities of a well functioning anxiolytic drug. It is believed by the inventors that deramciclanc satisfies this need in the art.

Additional objects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The objects and advantages of the invention will be realised and attained by means of the elements and combinations particularly pointed out in the appended claims.

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.

5 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the number of responders (at least 50 % reduction in HAM-A scale).

DETAILED DESCRIPTION OF THE INVENTION

10

An object of the present invention is to provide an oral daily dosage of about 20 to about 30 mg of deramciclane for the treatment of disorders of serotonergic systems in humans. One disorder of the serotonergic system treatable according to the present invention is anxiety, for example chronic anxiety. The present invention also
15 includes the treatment of GAD. Another object of the present invention is directed to the treatment of chronic anxiety where the patient does not experience relapse of the anxiety.

Another object of the present invention is directed to the method of treating
20 depression in a human.

It is still a further object of the invention to provide a treatment regimen of deramciclane that does not require, to avoid withdrawal effects, diminishing the treatment dosage before terminating the treatment. In other words, in this embodiment,
25 the patient may continue receiving the full treatment dosage up to the point of termination of the treatment, and will not suffer withdrawal effects that would have otherwise followed using other conventional treatments. In the regimen of the invention a standard daily dosage of deramciclane is given to the patient for a period long enough, e.g. for from three weeks to ten years, e.g. for from two months to five years, e.g. for
30 from eight months to two years, to cause relief of the symptoms, whereafter the treatment is abruptly terminated. By the term "abruptly terminated" it is meant that the dose is decreased within 24 hours from the standard dosage to less than a fourth of the standard dose, preferably to zero.

A dosage of about 30 mg of deramciclane may be used, for example in a conventional relatively fast release formulation. When the corresponding slow release formulation is used, the dosage may be also lower, for example about 20 mg.

5

In the present invention it has been discovered that when treating disorders relating to anxiety in humans with deramciclane the most effective clinical response was obtained with an oral daily dosage of about 30 mg. When deramciclane was used in the treatment of anxiety, specifically GAD, the oral daily dosage of 30 mg
10 was found to express the best response on Hamilton Anxiety Scale (HAM-A). Further, in the pairwise comparison of the responder criterion (at least 50 % reduction in HAM-A scale) between the deramciclane dosage and placebo, the oral daily dosage of 30 mg was statistically better than placebo.

15 In addition, in the present invention it has been discovered that deramciclane is effective in treating depressive disorders in humans. Specifically, the same oral daily deramciclane dosage of 30 mg, which was effective in the treatment of anxiety was found to be effective on the depressive symptoms in the Montgomery Åsberg Depression Rating Scale (MADRS).

20

The use of the term “about” with respect to the dosage amounts includes the natural industry variation in dosage amounts of drugs administered to patients. For example, a variation of $\pm 5\%$ in a given dosage amount in the methods of the present invention would be included by the term “about” in the present invention.
25 For example, a dosage $30\text{ mg} \pm 5\%$ is included within the phrase “about 30 mg” in an embodiment of the present invention.

EXAMPLE

30 The efficacy of deramciclane in the treatment of anxiety, specifically GAD, was studied in a randomised placebo-controlled double-blind study. In addition, the dosage dependency of the effects of deramciclane was evaluated. Total of 208 patients were included in the study. The subjects were randomly assigned to four parallel groups to receive one tablet twice daily (b.i.d) of a placebo, 5mg

(=10mg/day), 15mg (=30mg/day), or 30mg (=60mg/day) deramciclane. The study started with a one-week placebo run-in period, followed by an eight-week placebo-controlled active treatment and a two-week placebo washout period.

- 5 The efficacy of deramciclane on anxiety symptoms was studied by the efficacy variable Hamilton Anxiety Scale (HAM-A), analyzing the change in the score and using responder criterion (at least 50 % reduction in HAM-A total score).

- 10 The efficacy of deramciclane on depressive symptoms was studied using Montgomery Åsberg Depression Rating Scale (MADRS).

RESULTS

Anxiety

- 15 The HAM-A score decreased 14.5 points from baseline in groups receiving either 15 mg b.i.d or 30 mg b.i.d. dose. However, only the 15 mg b.i.d group differed statistically significantly from placebo ($p=0.006$). No difference was found between the 5 mg b.i.d and placebo. Accordingly, increasing the dose over 15mg b.i.d did not increase the efficacy any more.

- 20 Number of responders (at least 50 % reduction in HAM-A scale) is presented in Figure 1. The responder criterion was reached by 54 % ($n=27$), 57% ($n=31$), 76% ($n=39$) and 70% ($n=37$) of patients on placebo, 5 mg, 15 mg and 30 mg b.i.d. dosing, respectively. In comparison between the deramciclane dose levels and placebo, only
25 15 mg b.i.d. was statistically better than placebo ($p=0.020$).

Lack of withdrawal symptoms

- After stopping the above described 8-week treatment period no discontinuation effects were seen (measured by the Physician's Withdrawal Checklist, PWC). This is
30 different and surprising from the experiences with the most other efficacious drugs used for the treatment of anxiety.

Table 1. The PWC values at 8 weeks (when the treatment was stopped) and at 10 weeks (after a two week wash out period)

dosage	after 8 week treatment	after two-week wash-out
placebo	12 (10)	12 (11)
5 mg b.i.d deramciclanc	9 (7)	9 (8)
15 mg b.i.d deramciclanc	7 (8)	8 (7)
30 mg b.i.d deramciclanc	8 (8)	8 (7)

Mean (SD)

5

In conclusion, deramciclanc did not cause any withdrawal symptoms after abrupt discontinuation of the treatment. Therefore, it may be used as a treatment for serotonergic diseases without any withdrawal effects.

10 Depression

MADRS scores decreased similarly and statistically significantly in both 15 mg b.i.d and 30 mg b.i.d groups (7.7 and 8.0 points, $p=0.028$ and 0.016 , respectively). 5 mg b.i.d dose was ineffective. Thus, both the oral daily dosages of 30 mg and 60 mg of deramciclanc were found to be effective on the depressive symptoms.

15

Although the invention has been illustrated by the preceding example, it is not to be construed as being limited to the materials employed therein; rather, the invention is directed to the generic area as herein disclosed. Various modifications and embodiments thereof can be made without departing from the spirit or scope thereof.

20

CLAIMS:

1. Use of deramciclane in the manufacture of a medicament for the treatment of disorders relating to the serotonergic system in humans in an oral daily dosage of about 20 to 30 mg.
5
2. The use according to claim 1, wherein the disorder is anxiety.
3. The use according to claim 2, wherein the anxiety disorder is chronic.
- 10 4. The use according to claim 3, wherein the patient does not experience relapse of the disorder.
5. The use according to claim 4, wherein the disorder is generalised anxiety disorder.
15
6. The use according to claim 5, wherein the daily dosage is about 30 mg.
7. Use of deramciclane in the manufacture of a medicament for the treatment of disorders relating to depression in humans.
20
8. The use according to claim 7, wherein deramciclane is administered orally.
9. The use according to claim 8, wherein an oral daily dosage of about 30 mg is used.
25
10. The use according to any of claims 1 to 9, wherein a once-a-day formulation is used.
11. Manufacture of deramciclane for the treatment of disorders relating to the
30 serotonergic system, to be administered to a human in standard daily dosage for a long enough period to cause relief of the symptoms, followed by an abrupt termination of the administration.

12. Manufacture according to claim 11, wherein the standard daily dosage is given to the patient for at least three weeks.

13. Manufacture according to claim 11 or 12, wherein the standard daily dosage
5 is about 20 to 30 mg.




Fig. 1